Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 176
News
News | 04 March 2021

Merck FY20 sales up 8.6% euro 17.5 bn

Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.

News
News | 02 March 2021

DSM increases price for polyamide 6 and 66 in EMEA

The price increases are due to the rising costs of raw materials.

News
News | 02 March 2021

DSM secures victory in patent infringement litigation against Anhui Tiger

Tiger can no longer make an important biotin intermediate using a DSM patented process.

News
News | 02 March 2021

Piramal Enterprises cashing in on opportunities: ICICI Securities

PEL will explore the PLI scheme and apply if its beneficial.

News
News | 01 March 2021

Accelerated growth in pharma depends on the right policies: Experts

A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders

News
News | 01 March 2021

Pharma stalwarts demystify COVID-19 impact on industry

Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.

News
News | 26 February 2021

Bayer delivers robust performance despite pandemic

The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.

News
News | 26 February 2021

IPA goes all out to develop a future roadmap for pharma sector

Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.

News
News | 26 February 2021

India approves PLI scheme for pharmaceuticals

Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.

News
News | 26 February 2021

Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda

The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.

News
News | 25 February 2021

Pharma industry bullish on complex generics and biosimilars

While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side

News
News | 25 February 2021

Granules India gets USFDA approval of acetaminophen, aspirin and caffeine tablets

ranules now has a total of 38 ANDA approvals from US FDA.

News
News | 24 February 2021

Aurobindo Pharma to acquire 26% ownerships solar power companies

The company will be holding 26% of the share capital in each of the solar power generating companies.

News
News | 24 February 2021

USFDA denies Sun Pharma Advanced Research’s appeal of NDA for Taclantis

The company will review FDA's response and decide on appropriate next steps soon.

News
News | 23 February 2021

Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits

Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.

News
News | 22 February 2021

“Minus 20°C is sometimes trickier than minus 70°C”

DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic

News
News | 20 February 2021

Unichem Laboratories receives ANDA approval for Apremilast Tablets

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .

News
News | 20 February 2021

Zydus Cadila receives final approval from USFDA for Droxidopa capsules

It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.

News
News | 20 February 2021

Lupin receives approval for Droxidopa capsules

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness

News
News | 20 February 2021

Dr. Reddy's initiates process for emergency use authorization of Sputnik V

Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.

Startup

Digitization